Then, we investigated the influence of SLCO1B1 gene polymorphisms and CYP2C19 metabolizer phenotypes on the sdLDL-C lowering efficacy of statin drugs in patients with CAD. The gene discussed is SLCO1B1; the disease is coronary artery disorder.